So much to say, so little space. FDA-led studies assess risk information on social media
How should pharma companies use the limited character space in a promotional tweet? While including risk information in the body of a post made patients more likely to recognize potential dangers, new FDA-led research suggests it also made them less likely to pursue more information.
The FDA said in draft guidance back in 2014 that if a company promotes a drug on social media, it should also include the most serious risks in the body of that post — regardless of character-space limitations (CSL). Regulators told drugmakers to include a link devoted solely to the communication of risks.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.